PM.20.029 – GENEtics in personalized Medicine And Prevention (GENE-MAP)

Route: Personalised medicine: the individual at the centre

Cluster question: 081 How will our knowledge of genetics play a role in analysing, screening for, and treating diseases?

Genetics influences risk of every disease and response to interventions from birth onwards, can be easily and comprehensively measured, at any point in time and for many diseases for <30 euros per sample. These include common diseases which clinicians see and treat daily and burden our society. Therefore, genetic risk assessment enables early disease identification and prevention compared to classical time-sensitive clinical biomarkers. Yet, (clinical) implementation is slow, and general availability of this personalized information to patients and the public is lacking, in contrast to other EU countries (e.g., Estonia, Finland, UK). Simultaneously, the public wants access to this, as demonstrated by more than 20 cluster questions and the personalized medicine and prevention in healthcare routes in the national science agenda. To improve clinical care and public availability of personalized medicine, we will establish a consortium of Dutch experts in genetics, medicine, epidemiology, public health economics, societal implementation and ethics. The resulting platform provides personalized insight into individual health state and ways to modulate risk for three main disease categories; cardiovascular, oncological and psychiatric. This project utilizes pre-existing but currently unconnected datasets and initiatives, builds new datasets, and harmonizes methods and interpretations. Specifically: 1) Validate genetic risk assessment tools in Dutch clinical and population datasets, with attention for ethnic and gender diversity; 2) Develop solutions for logistical, administrative, societal, ethical and legal implementation hurdles; 3) Identify existing disease-specific preventive options through lifestyle, diet, exercise and participation in populations screening programs; 4) Integrate all into a secure individualized risk assessment tool, allowing uploading and evaluation of genetic and non-genetic factors, disease risks and preventive options; 5) Provide guidelines on appropriate clinical and public use of this tool.
Persons involved: Prof. Dr. Peter Devilee (LUMC), Prof. Dr. MD. Folkert Asselbergs (UMCU, UCL), Prof. Dr. Lude Franke (UMCG), Prof. Dr. Danielle Posthuma (VUMC), Dr. Tessel Rigter (RIVM), Prof. Dr. Lili Milani (University of Tartu, Estonia), Prof. Dr Jerry Rotter (UCLA, USA), Dr. MD. Katherine Hajek (Sanford Health Systems, USA), Dr Priit Palta (FIMM, Finland), Dr. Joyce van Meurs (EMC), Dr. Marieke van Dooren (EMC), Dr. Sam Riedijk (EMC), Jeroen van Rooij (EMC), Boy Vijlbrief (EMC)


disease risk prediction and modulation, genetics, individual autonomy, Personalized medicine, Prevention

Other organisations

EMC, Estonia, FIMM, Finland, Leiden Universitair Medisch Centrum (LUMC), Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Sanford Health Systems, UCL, UCLA, UMCG, UMCU, University of Tartu, USA), VU Medisch Centrum Amsterdam (VUMC)


Organisation Erasmus Medical Center Rotterdam (EMC)
Name Prof. dr. A.G. (André) Uitterlinden